Vertex Signs Letter of Intent for Cystic Fibrosis Therapy in Canada
MT Newswires Live
Jul 06
Vertex Pharmaceuticals (VRTX) said Monday it signed a letter of intent with the pan-Canadian Pharmaceutical Alliance for its cystic fibrosis therapy Alyftrek.
The agreement covers the triple-combination therapy for patients aged 6 years and older with at least one F508del mutation or another responsive CFTR mutation.
Vertex said it will now begin discussions with provincial and territorial governments to support the public listing of Alyftrek through publicly funded drug programs across Canada.
Shares of the company were down nearly 1% in Monday trading.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.